SCHEMBL22890776

SCHEMBL22890776

Cc1nc(CO)c(Cl)c(C)c1C#N

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
HTT P42858 2/20 0.45
GLA P06280 1/20 0.45
TSHR P16473 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.39
MAPK1 P28482 1/20 0.39
THRB P10828 1/20 0.38
ALDH1A1 P00352 4/20 0.37
GAA P10253 4/20 0.37
KDM4E B2RXH2 6/20 0.36
MAPT P10636 2/20 0.36
CACNA1B Q00975 1/20 0.36
APBA1 Q02410 1/20 0.36
APOBEC3G Q9HC16 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
POLB P06746 1/20 0.35
POLQ O75417 1/20 0.34
LRRK2 Q5S007 1/20 0.34
CYP1A2 P05177 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31644374 0.86 HTT (0.53) MEN1KMT2AHTTGLATSHR
SCHEMBL22890375 0.86 ALDH1A1 (0.49) MEN1KMT2AHTTGLATSHR
SCHEMBL22890017 0.83 MAPK1 (0.41) MEN1KMT2AHTTGLATSHR
SCHEMBL29771532 0.83 MAPK1 (0.41) MEN1KMT2AHTTGLATSHR
SCHEMBL2614484 0.77 HTT (0.63) MEN1KMT2AHTTGLATSHR
SCHEMBL22890037 0.73 ALDH1A1 (0.50) MEN1KMT2AHTTGLATSHR
SCHEMBL29741335 0.73 ALDH1A1 (0.50) MEN1KMT2AHTTGLATSHR
SCHEMBL22890386 0.70 LRRK2 (0.46) MEN1KMT2AHTTGLATSHR
SCHEMBL9909077 0.69 ALDH1A1 (0.46) MEN1KMT2AHTTGLATSHR
SCHEMBL4673214 0.68 HTT (0.58) MEN1KMT2AHTTGLATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230077268-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS E-SCAPE BIO, INC. 2023-03-09 US disclosed
US-11427558-B1 Indazoles and azaindazoles as LRRK2 inhibitors ESCAPE Bio, Inc. (US) 2022-08-30 US disclosed
EP-3997081-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS Escape Bio, Inc. (US) 2022-05-18 EP disclosed
CN-114450274-A Indazoles and azaindazoles as LRRK2 inhibitors 伊斯凯普生物公司 2022-05-06 CN disclosed
WO-2021007477-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS E-SCAPE BIO, INC. (US) 2021-01-14 WO disclosed
WO-2021007477-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS E-SCAPE BIO, INC. (US) 2021-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11427558-B1 Indazoles and azaindazoles as LRRK2 inhibitors LRRK2, PARK7, GDI2 MEN1 2815/4885KMT2A 361/4885HTT 293/4885
US-20230077268-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS LRRK2, PARK7, GDI2 MEN1 2815/4885KMT2A 361/4885HTT 293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.